Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). A survey was conducted in all Dutch academic haematology centres on their current diagnostic, prophylactic and therapeutic approach towards IFD in the context of azole-resistance. In all 8 centres, a haematologist and microbiologist filled in the questionnaire that focused on different subgroups
a triazole-resistant A. fumigatus result in a high mortality and the best diagnostic and treatment approach is uncertain. 5, 8 We conducted a survey on fungal diagnostics, antifungal prophylaxis and treatment in all Dutch academic haematology centres. The survey facilitated the development of a consensus approach towards the management of invasive aspergillosis (IA) in a context of rising azole-resistance.
| MATERIAL S AND ME THODS
A questionnaire was sent to a haematologist and a microbiologist with special interest in supportive care and medical mycology respectively and both parties were asked to answer as a team for their centre. The questionnaire focused on (i) primary prophylaxis during AML chemotherapy, during allogeneic hematopoietic stem cell transplantation (allo-HSCT) and at the time of GVHD. (ii) How was screened for IFD and which diagnostic tests were performed.
(iii) The current antifungal treatment for different clinical scenarios. The results were processed and during a consensus meeting the protocol for The Azole-Resistance MANagement (AzoRMan)
Study was developed and implemented.
| RE SULTS

| Prophylaxis
| Prophylaxis directed against Candida
Fluconazole is given during neutropaenia of >10 days in 4/8 centres at very different dosages and amphotericin B oral suspension was used in 2 (Table 1) . One centre also uses amphotericin B lozenge.
One centre starts fluconazole when surveillance cultures grow
Candida. If surveillance cultures show Candida species resistant to fluconazole, some centres switch to amphotericin B suspension and one centre adds amphotericin B suspension to fluconazole.
Finally, one centre stops fluconazole and no other prophylaxis is initiated.
| Mould-active prophylaxis
Only one centre applies mould-active prophylaxis (itraconazole) during chemotherapy induced neutropaenia of >10 days and during myeloablative allo-HSCT. Therapeutic drug monitoring of itraconazole is performed and when no effective plasma concentrations are reached, a switch to voriconazole is made. In another centre nebulised liposomal amphotericin B (L-AmB) at 15 mg QD, twice weekly is used for this purpose. All centres start mould-active prophylaxis when corticosteroids are given for GVHD but the drugs of choice differ (Table 1) .
and consisted of fluconazole and/or amphotericin B suspension. Mould-active prophylaxis was given to acute myeloid leukaemia patients during chemotherapy in 2 of 8 centres. All centres used azole prophylaxis in a subset of patients with graft-versus-host disease. A uniform approach towards the diagnosis and treatment of IFD and in particular azole-resistant Aspergillus fumigatus was lacking. In 2017, all centres agreed to implement a uniform diagnostic and treatment algorithm regarding invasive aspergillosis with a central role for comprehensive diagnostics and PCR-based detection of azole-resistance. This study (DB-MSG 002) will re-evaluate this algorithm when 280 patients have been treated. A heterogeneous approach towards antifungal prophylaxis, diagnosis and treatment was apparent in the Netherlands. Facing triazole-resistance, consensus was reached on the implementation of a uniform diagnostic approach in all 8 centres.
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| Diagnosis
| Diagnostic procedures
A chest CT is routinely performed in all centres after 3 to 5 days of neutropenic fever without an infectious focus despite antibiotic therapy (Table 2) . When the chest CT scan shows pulmonary infiltrates a broncho-alveolar lavage (BAL) with galactomannan (GM) detection and fungal culture is performed in all centres (if clinically feasible). Twice weekly serum GM monitoring as a screening tool is performed in one centre only. Two centres perform an Aspergillus DNA PCR on BAL routinely; in one centre this is done only when BAL GM is positive or when an EORTC compatible radiological finding is suggestive of an IFD.
| Susceptibility testing
Different Aspergillus susceptibility testing methods are used:
VIPcheck™ or Etest followed by confirmation with testing according to the European Committee on Antibiotic Susceptibility
Testing (EUCAST) method when resistance is suspected based on the screening assay ( One centre sends BAL samples to the RefLab for PCR testing.
| Treatment
Suspected invasive fungal infection:
All centres use voriconazole as the initial treatment for patients in a respiratory stable condition suspected of having an IFD while waiting for the microbiological tests (Table 4) 
| Therapeutic drug monitoring
| Voriconazole
Two centres do not perform therapeutic drug monitoring (TDM).
Two centres do TDM when toxicity or treatment failure is suspected.
The other centres routinely perform TDM.
| Posaconazole
Three centres always perform TDM and two centres do not. The other three centres perform TDM on indication only.
| Triazole resistance data
In 2016, A. fumigatus isolates from 784 clinical patients were screened for triazole resistance using a 4-well agar plate (VIPcheck™). Isolates that grew on the triazole-containing agar have a high probability of resistance and were sent to the Reflab for phenotypic and genotypic characterisation. 101 isolates (12.9%) were triazole-resistant, which was higher than 2014 (7.2%) and 2015 (10.7%). In individual centres, resistance ranged from 9.5% to 20.5%. 6 Recently, a nationwide Dutch cohort study reported data from 144 patients with influenza pneumonia admitted to all 8 University Intensive Care Units. 23 patients (16%)
were diagnosed with influenza-associated invasive aspergillosis and triazole resistance was reported in 29% of those with a positive A. fumigatus culture. 9 The clinical relevance of triazole resistance was also 
| Prophylaxis directed at Candida
The European Conference on Infections in Leukaemia (ECIL) 5 guidelines on antifungal prophylaxis recommends fluconazole (400 mg q24 h) when the mould infections are rare and a mould-directed diagnostic approach is in place (B-I). 10 The latter is the case in all centres that were surveyed but the dose of fluconazole varies among centres and is generally lower than was used in most randomised trials (400 mg q24 h). [11] [12] [13] [14] [15] Some studies suggest that lower doses may suffice. 16 Three centres use oral amphotericin B as primary prophylaxis 
| Mould-active prophylaxis
The advantage of primary mould-active prophylaxis with posaconazole was shown in two randomised trials. 13, 14 The Dutch guideline on antifungal management as well as the ECIL-5 guideline recommends posaconazole for primary prophylaxis (A-I) when the incidence of mould infections is high. 10, 19 Firm criteria for what constitutes `high risk` are lacking but it has been proposed that subpopulations with >8%-10% fall into this category. Unfortunately, reliable data on the local prevalence of mould infections are often lacking. 20 One centre administers aerosolised L-AmB twice weekly for the prevention of IFD in AML patients undergoing intensive chemotherapy. Its efficacy and cost-effectiveness have been demonstrated in a single-centre randomised placebo-controlled trial and an observational study. 21 therapy and proceed to BAL sampling when infiltrates are documented. Indeed, a survival benefit of azole prophylaxis compared with a diagnostic-driven approach has not been convincingly shown and so both continue to be reasonable strategies. 
| Mould-active prophylaxis in GVHD
| Susceptibility testing
Azole-resistance was rare in The Netherlands before the year 2000 but its prevalence has continued to increase since then. 25 It is currently based on a limited number of resistance-associated mutations (RAMs) in the cyp51A-gene (TR 34 /L98H, TR 53 , and TR 46 /Y121F/ T289A) and is most likely caused by the environmental use of azole fungicides. 7, 26, 27 The TR 34 /L98H and TR 46 /Y121F/T289A accounted for 83% of resistance mutations in 2016. 6 IDSA guidelines do not recommend standard susceptibility testing but these guidelines cannot be applied to The Netherlands. 23, 28 Case series indicate that IA caused by azole-resistant Aspergillus, is associated with a very high mortality. 5, 8 The diagnostic tools used for the detection of azoleresistance vary from centre to centre. Most perform agar-based screening assays for resistance (VIPcheck™ testing). Phenotypic azole-resistance testing according to the EUCAST method is performed by the National mycology reference laboratory only (RefLab). Four centres directly send Aspergillus strains to the RefLab and three await the result of the screening assay.
Only very recently, the clinical validity and relevance of PCRbased susceptibility testing on BAL was demonstrated and may explain the limited uptake of resistance detection by PCR at the time of the survey. The AsperGenius ® qPCR is a multiplex PCR and can detect the presence of Aspergillus DNA and in addition detect the 2 mutations described above. 8, 29 In a recent study the diagnostic performance was evaluated on BAL-samples in 201 patients. 8, 29 The Aspergillus BAL qPCR, had a sensitivity of 89% and a specificity of 89% and was able to detect A. fumigatus that carried resistance-associated mutations (RAM) in the majority of patients, even in culture-negative BAL. Furthermore, this study showed that response to voriconazole therapy, when given to patients infected with a resistant A. fumigatus was poor. 
| Treatment
The ECIL-6 guideline attributes an A-I recommendation to both voriconazole and isavuconazole for the treatment of IA. 30 Unfortunately, in 2016 surveillance data showed that triazole resistance was pre- Although some studies suggest a relation between voriconazole serum levels and the incidence of adverse events, randomised clinical trials that convincingly show the value of TDM are still lacking. and did this based on locally generated evidence that supports its (cost-)effectivity. 21, 22 Finally, the continued use of oral amphotericin-B solution as anti-yeast prophylaxis (on top of fluconazole) was driven by the fact that it is a harmless intervention (as no systemic toxicity occurs with a non-absorbed drug) and because with this policy, the incidence of candidaemia had been very low with this policy for more than 15 years. Therefore, these centres were reluctant to change a safe policy that seems to be very efficacious.
| Protocol
Following 
| CON CLUS ION
This survey shows the heterogeneous landscape in the prevention, diagnosis and treatment of IA in The Netherlands. In the context of the rapidly increasing prevalence of azole-resistance, the AzorMan study was implemented to evaluate a uniform diagnostic and therapeutic approach. org/0000-0002-3224-3969
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